Home » Ipsen’s Partner Roche Says Taspoglutide Meets Endpoint in Phase III Trial
Ipsen’s Partner Roche Says Taspoglutide Meets Endpoint in Phase III Trial
Ipsen, a global biopharmaceutical group, Thursday announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients
with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human sequence.
MarketWatch
MarketWatch
Upcoming Events
-
07May
-
14May
-
30May